Standard Contracts
EX-10.17 21 d503089dex1017.htm EX-10.17 Execution Version EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • May 5th, 2020 • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000007Exclusive Ip License Agreement • June 6th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000007 (this “Agreement”) is entered into as of December 27 2010 (the “Effective Date”) by and between. Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
EXCLUSIVE IP LICENSE AGREEMENTExclusive Ip License Agreement • February 27th, 2024
Latvian Institute of Organic Synthesis, a public research organization, located at Aizkraukles str. 21, Riga, LV-1006, Latvia (“Licensor”) AND SIA “xxx” (reg. # xxx) a limited liability company, located at xxx (“Licensee”)
First Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the First Amendment (“Amendment”) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on July 12, 2012 (the “Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
Second Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • March 14th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000007 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
First Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the First Amendment (“Amendment”) to the Exclusive IP License Agreement for RQ-00000007 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on July 12, 2012 (the “Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE IP LICENSE AGREEMENTExclusive Ip License Agreement • June 30th, 2021 • Electric Last Mile Solutions, Inc. • Motor vehicles & passenger car bodies • Delaware
This EXCLUSIVE IP LICENSE AGREEMENT (together with all Exhibits hereto, this “Agreement”) is executed as of April 9, 2021 (the “Execution Date”) and entered into by and between SF Motors, Inc., d/b/a SERES (the “Licensor”), a Delaware corporation and Electric Last Mile, Inc. (“Licensee”), a Delaware corporation (collectively, the “Parties,” or each, individually, a “Party”).
Second Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • March 14th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
